

# Impact of lactic acid on human macrophage polarization

-----  
Introduction: In established tumors, tumor-associated macrophages (TAM) orchestrate unresolving cancer-related inflammation (M1 properties) and produce growth factors that favor tumor growth, metastasis and angiogenesis (M2-like properties). To date, factors that confer M1 and M2 functional properties to human macrophages remain unknown.

Objective: Elevated levels of lactic acid (LA) being common in most solid tumors, we analyzed the impact of lactic acidosis on human monocyte differentiation.

Methods: Human monocytes were differentiated in GM-CSF, in the absence or presence of 10 mM LA and their phenotype was analyzed at different time-points.

Results: We report that prolonged lactic acidosis induces monocyte differentiation into macrophages (GM+LA-M $\phi$ ) harboring an unconventional mixed M1 and M2 functional phenotype. In addition to producing high levels of many inflammatory cytokines and low levels of IL-10, GM+LA-M $\phi$  produce many growth factors (i.e. VEGF, PDGF, OSM, HB-EGF and IL-20) and express prototypic M-CSF-dependent genes. These effects were partly due to the ability of lactic acid to allow autocrine M-CSF consumption by monocytes under differentiation, despite the presence of GM-CSF.

The impact of LA on macrophages is not mimicked by acidosis. It requires the import of lactate into the cells, its oxidation into pyruvate, which induces HIF-1 stabilization. Finally, primary ovarian cancer cells are glycolytic and induce M1/M2 cell generation through an MCT-dependent mechanism. Finally, we show for the first time that most of the TAM present in human ovarian tumors exhibit a mixed M1 (production of IL-8 and IL-1) and M2 (secretion of VEGF) phenotype.

Conclusion: These results identify tumor-derived LA as a missing link reconciling the M2-like features of human TAM with their inflammatory properties and reinforce the potential of therapies that reduce tumor glycolysis or tumor-associated acidosis.

-----

Keywords : Macrophages, Tumor, Immunometabolism

Authors :

References : , , ,

## Authors

**Clément ADAM** 1, Léa PAOLINI 1, Guillaume TCHERKEZ 2, Laurence PREISSER 3, Vincent PROCACCIO 4, Yves DELNESTE 3, Pascale JEANNIN 3,

1. CRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, FRANCE
2. Research School of Biology, ANU Joint College of Science, Canberra ACT, Canberra, AUSTRALIA
3. CRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, Angers, FRANCE
4. Institut MitoVasc, Université d'Angers, UMR CNRS 6015 INSERM 1083, Angers, Angers, FRANCE
5. CRCINA, INSERM, Université de Nantes, Université d'Angers, Angers,, Angers, FRANCE